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Purpose: To study the effect of 3 Schlemm’s canal (SC) microinvasive glaucoma surgery (MIGS) devices on
outflow facility.
Design: Paired comparisons, randomized design, baseline-controlled study.
Participants: Thirty-six pairs of dissected anterior segments from donated human eye bank eyes without
glaucoma were studied. A baseline measurement was collected from each eye to serve as its control.
Methods: Using a constant pressure perfusion method, outflow facility was measured in paired eyes from
human donors. Measurements were made at perfusion pressures of 10 mmHg, 20 mmHg, 30 mmHg, and 40
mmHg. Outflow facility was measured before (baseline control) and after the implantation of an SC glaucoma
drainage device or sham procedure. Three sets of experiments were carried out comparing 1 and 2 iStent
Trabecular Micro-Bypass Stents and 2 iStent Inject implants with the Hydrus Microstent.
Main Outcome Measures: Change in outflow facility from baseline or contralateral eye.
Results: After Hydrus placement, the outflow facility increased from 0.230.03 ml/minute per millimeter of
mercury at baseline to 0.380.03 ml/minute per millimeter of mercury (P < 0.001). The percent increase in outflow
facility was 7921% for the Hydrus and 1116% for the 2 iStent Inject devices, a difference that was significant
(P ¼ 0.018). Outflow facility with 1 iStent (0.380.07 ml/minute per millimeter of mercury) was greater than
baseline (0.280.03 ml/minute per millimeter of mercury; P ¼ 0.031). The 1 iStent showed a greater increase in
outflow facility from baseline (0.100.04 ml/minute per millimeter of mercury) compared with the sham procedure
(e0.080.05 ml/minute per millimeter of mercury; P ¼ 0.042). No other significant differences were found.
Conclusions: The longer the MIGS device, and thus the more SC that it dilates, the greater the outflow
facility. Ophthalmology Glaucoma 2020;3:114-121 ª 2019 by the American Academy of Ophthalmology. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Glaucoma, a leading cause of blindness worldwide,1 is
treated by lowering intraocular pressure (IOP).2,3
Typically, medical therapy is used as the first line of
treatment, followed by more invasive steps such as
glaucoma filtration surgery.4e6 Recently, several micro-
invasive glaucoma surgery (MIGS) techniques have been
developed and are being used earlier in the treatment para-
digm. These MIGS techniques share several common traits,
including an ab interno approach that is minimally traumatic
to the target area, a safety profile that avoids serious com-
plications allowing for rapid recovery, and an IOP-lowering
efficacy that justifies the intervention.7e9
Outflow MIGS devices are a subset of MIGS techniques
that improve drainage of aqueous humor through Schlemm’s
canal (SC). Outflow MIGS devices reduce the resistance to
outflow at the level of the trabecular meshwork (TM) by
creating a bypass or removing the TM altogether. As soon as
the TM is bypassed, aqueous humor can flow into collector
channels, aqueous veins, and episcleral veins with less
resistance. Growing scientific evidence supports the impor-
tance of bypassing the TM and dilating SC to reduce IOP.10
Multiple scientific studies have been published on the ef-
fect of several different outflow MIGS implants on outflowlsevier Incfacility. The most common laboratory approach to test these
implants is to isolate the conventional outflow pathway
including the TM, SC, and aqueous humor outflow network
that is contained within the anterior segment of a human eye.
This approach provides a unique opportunity to directly
compare the differences in outflow facility effects among the
implants. These studies include the Hydrus Microstent11,12
(Ivantis, Inc, Irvine, CA), first-generation iStent Trabecular
Micro-Bypass (Glaukos Corp, San Clemente, CA),13 and
second-generation iStent Inject14 (Glaukos Corp). The
current study adds to the literature by comparing all 3
implants and a sham procedure within a single laboratory.Methods
Test Articles
The first implant evaluated in the study was the Hydrus Microstent,
which is a nitinol (nickel-titanium) scaffold approximately 8 mm in
length with an inlet of 260 mm in diameter, designed to keep the SC
dilated and maintain an opening in the TM. The second implant
evaluated was the iStent TrabecularMicro-Bypass Stent, which is an
L-shaped titanium stent with a 0.25-mm  120-mm (bore diameter).
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Figure 1. Diagram showing experimental design of study eyes and procedures.
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was the iStent Inject, which is a cylindrical titanium stent with a
central lumen of 80 mm and side lumens of 50 mm. Three sets of
experiments were carried out, as summarized in Figure 1.
Tissue Preparation
This study used enucleated human donor eyes. Before the study
began, the project was evaluated by The Center for Clinical Research
and Technology at Case Western Reserve University and determined
not to be a human subjects research study under Federal regulation 45
CFR46 or 21 CFR 56. Therefore, institutional review board approval
and informed consent were not needed. The study was performed in
compliance with the principles of the Declaration of Helsinki. Thirty-
six pairs of globes were obtained from Eversight, Minnesota Eye
Bank, and Saving Sight. Four of the pairs were rejected because of
postmortem age or leaks in the tissue or the system. The remaining
globes were wrapped in saline-wetted gauze, packed in moist con-
tainers cooled in crushed ice, and received within 48 hours of death.
The average time from death of the donor until the start of the
experiment was 45.712.7 hours. The eligible donors’ lenses were
phakic, and the donors had no known ocular disease history or had
undergone prior ocular surgery. The mean donor age was 67.19.9
years. Demographic information is summarized Table 1. The eyes
were dissected along the coronal equator, and the anterior segments
were prepared as described previously.11,12,15
Perfusion System
The outflow facility measurement apparatus contained fluid columns









One iStent vs. sham 11 70.34.5 10 white,
1 Hispanic
7
Two iStents vs. 2
iStent Injects
10 62.514.6 7 white, 2 black 2
Two iStent Injects vs.
Hydrus Microstent
11 67.18.4 7 white, 2 black 5
Total 32 66.810.0 26 white, 3 black,
2 Hispanic
14
CVA ¼ cerebrovascular accident; GI ¼ gastrointestinal.the tissue chamber holding the anterior segment. The tubing was
filled with 5.5 mM D-glucose in Dulbecco’s phosphate-buffered
saline. Perfusion pressures were controlled by setting the fluid in
the columns to heights corresponding to 10 mmHg, 20 mmHg, 30
mmHg, and 40 mmHg. During the perfusion time, the anterior
segments were submerged partially in perfusion fluid maintained at
34 C by a temperature-controlled water bath. Pressure transducers,
PowerLab 8/30 receiver (ADInstruments, Bella Vista, Australia),
and LabChart 7 software (ADInstruments Pty Ltd, Richardson, TX)
recorded perfusion pressures during the study.
Calculation of Outflow Facility
Outflow facility (C) values were calculated at each perfusion
pressure as the ratio of flow (F) to IOP: C ¼ FIOP. Individual C
values at each IOP were averaged.11 If the calculated outflow
facility was more than 1.0 ml/minute per millimeter of mercury,
either before or after the sham procedure or stent insertion, this
was a statistical outlier and taken as evidence of a leak. Based
on the Goldmann equation, a change in outflow facility (C) is
expected to show a linear relationship to IOP change.
Implant Study Design
Anterior segments were perfused sequentially at pressures of 40
mmHg, 30 mmHg, 20 mmHg, 10 mmHg, 20 mmHg, 30 mmHg, 40
mmHg, and 10 mmHg. Before implantation of the MIGS devices,
baseline outflow facilities for each anterior segment were calcu-
lated at each perfused pressure.
After the baseline outflow facility measurement was completed,






4 Acute hypoxic respiratory failure,
adenocarcinoma, cardiac arrest, lung
cancer, myocardial infarction, sepsis
43.85.3
7 Autoimmune encephalitis, cardiac arrest,




6 CVA, GI bleed, myocardial infarction,
pneumonia, renal failure, sepsis
42.19.1
17 Most common: myocardial infarction,
cardiac arrest, pneumonia, sepsis
43.67.1
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of the inferonasal quadrant was viewed directly under the dis-
secting microscope. The anterior segment was kept moist during
the device insertion or sham process. Choice of procedure was
randomized. Using the injector, the Hydrus device was advanced
approximately 3 clock hours into SC, with 1 to 2 mm of the
proximal end protruding into the anterior chamber. One to 2 iStents
were inserted into SC depending on the study.16,17 If 2 iStents were
used, they were placed at least 2 clock hours apart.17 The study
investigators were trained on how to insert the devices by an
experienced board-certified glaucoma specialist before the study
began. The iStent Inject device was inserted using the spring-
loaded applicator to puncture the TM and position the head and
side flow outlets in the SC, leaving the flange in the anterior
chamber. All attempts were made to place each implant in the
inferonasal region. The proper placement of all implants was
verified under high-magnification light microscopy, as shown in
Figure 2.
In total, 32 pairs of eyes were used in the study for a total of 64
samples. The eyes were assigned randomly to 3 different study
groups, as shown in Figure 1. In the first study group, 11 pairs ofFigure 2. Photographs showing placement of 3 Schlemm’s canal drainage
devices. A, Curved arrow shows a Hydrus Microstent scaffold within
Schlemm’s canal and the straight arrow indicates the inlet of the Hydrus
Microstent in the anterior chamber. B, Two iStents (arrows) with rails
within the Schlemm’s canal and snorkels open to the anterior chamber. C,
Two iStent Injects (arrows) positioned in the trabecular meshwork with
the head within Schlemm’s canal and the flange exposed to the anterior
chamber.
116eyes were used to measure changes in outflow facility after
implanting 1 iStent versus a sham procedure consisting of a
1-mm incision made with a 25-gauge needle through the TM
into SC in the inferonasal quadrant. In the second study group, 10
pairs of eyes were used to evaluate outflow facility change for 2
iStent implants versus 2 iStent Inject implants. In the third study
group, 11 pairs of eyes were used to compare 2 iStent Inject im-
plants versus 1 Hydrus Microstent.Results
The results from each of the study groups are shown in Table 2 and
Figures 3, 4, 5, and 6.
One iStent Device versus Sham Study
The first study compared 1 iStent implant versus sham surgery. No
significant difference was found between change in outflow facility
from baseline between the 2 groups (P ¼ 0.073). The single iStent
significantly increased outflow facility by 0.100.04 ml/minute per
mmHg when compared with baseline (P ¼ 0.031). This change
equated to a 31.511.3% increase from baseline. The sham surgery
did not affect outflow facility significantly (P ¼ 0.187). A significant
difference was found between the change in outflow facility when
comparing the iStent with sham surgery (P ¼ 0.042; Fig 3).
Two iStent Devices versus 2 iStent Inject
Devices Study
The second study compared 2 iStent implants versus 2 iStent Inject
implants. No significant difference was found in change in outflow
facility from baseline between the 2 groups (P ¼ 0.577). Two
iStent-implanted eyes were excluded because of leaks. The group
that received 2 iStent implants showed increased outflow facility
by 47.023.3% (n ¼ 8) from baseline, but this did not reach
significance (P ¼ 0.092). The 2 iStent Inject implants increased
outflow facility by 10.421.8% (n ¼ 10) from baseline and did not
reach significance (P ¼ 0.536). No significant difference was found
in the change of outflow facility between the iStent and the iStent
Inject groups (Fig 4).
Two iStent Inject Devices versus 1 Hydrus
Device Study
The third study compared 2 iStent Inject implants versus a
single Hydrus Microstent. No significant difference was found
in change in outflow facility from baseline between the
2 groups (P ¼ 0.43). The iStent Inject implants increased
outflow facility by 10.516.1% from baseline, but this was not
significant (P ¼ 0.52). The Hydrus device significantly
increased outflow facility by 79.321.2% from baseline
(P < 0.001). The mean outflow facility of the eyes implanted
with Hydrus device were 0.13 ml/minute per millimeter of
mercury more than those implanted with the iStent Inject de-
vice (P ¼ 0.017). In addition, eyes implanted with the Hydrus
device showed a greater change in outflow facility (P < 0.001)
and significantly higher percent change in outflow facility
(P ¼ 0.018) when compared with eyes implanted with the
iStent Inject device (Fig 5).
Table 2. Outflow Facility (Microliters per Minute per Millimeter of Mercury)
Study 1 (n [ 11)* Study 2 (n [ 10)y Study 3 (n [ 11)z
First Eye,








Hydrus Microstent P Valuex
Beforejj 0.280.03 0.440.09 0.073 0.220.04 0.260.06 0.58 0.280.04 0.230.03 0.43
After{ 0.380.07 0.360.07 0.851 0.310.05 0.310.09 1.00 0.250.03 0.380.03 0.017
Change# 0.100.04 e0.080.05 0.042 0.080.04 0.040.07 0.62 e0.020.03 0.140.02 <0.001
% Change 3211% e810% 0.096 4723% 1022% 0.27 1116% 7921% 0.018
Range** e38% to 74% e53% to 29% e5% to 190% e65% to 127% e47% to 119% 9%e275%
P valueyy 0.031 0.187 0.092 0.536 0.520 <0.001
Values are meanstandard error of the mean unless otherwise indicated. Boldface indicates statistical significance.
*One iStent vs. a sham procedure, n ¼ 11 pairs of eyes.
yTwo iStents vs. 2 iStent Inject implants, n ¼ 10 pairs of eyes.
zTwo iStent Inject implants vs. 1 Hydrus Microstent, n ¼ 11 pairs of eyes.
xComparing treatments, paired t test.
jjMean at baseline.
{Mean after microinvasive glaucoma surgery device placement.
#Mean change from baseline.
**Range of percent changes from baseline.
yyComparing before versus after, paired t test.
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The percent increase in outflow facility relative to baseline
among the implants was 79.321.2% for the Hydrus device
(n ¼ 11; P < 0.001), 31.511.3% for 1 iStent implant (n ¼ 11;
P < 0.05), 47.023.3% for 2 iStent implants (n ¼ 8;
P < 0.001), and 10.413.0% for the pooled iStent Inject im-
plants (n ¼ 21; P ¼ 0.807). The data are summarized in Table 2
and Figure 6.
Discussion
Previous studies compared the Hydrus Microstent and
iStent.11,12 These studies were performed using the same
perfusion methods and techniques as the current study.
Therefore, it is possible to compile all data to obtain an
even more robust comparison of the MIGS devicesFigure 3. Graph showing the results of study 1, implantation of 1 iStent
(G1) versus sham procedure. Eleven pairs of globes were tested, with 1
randomly assigned globe receiving 1 G1 and the paired eye undergoing a
sham procedure. The percent change in outflow facility comparing the 2
procedures was significant (P ¼ 0.042). The bars indicate percent change
from baseline outflow facility (meanstandard error of the mean).evaluated here. Including this study, 35 eyes receiving the
Hydrus Microstent, 20 eyes receiving 2 iStent devices,
and 21 eyes receiving 2 iStent Inject have been tested.
Overall, the Hydrus Microstent increased outflow facility
by 0.170.02 ml/minute per millimeter of mercury
(75.111.7%; P < 0.001), 2 iStent implants increased
outflow facility by 0.080.03 ml/minute per millimeter of
mercury (39.311.3%; P ¼ 0.051), and 2 iStent Inject
implants increased outflow facility 0.010.04 ml/minute
per millimeter of mercury, although this was not
significant (10.413.0%; P ¼ 0.88). When comparing
implantation of the 2 iStents with implantation of the
Hydrus Microstent, the Hydrus eyes showed higher
outflow facility (P ¼ 0.007), higher increase in outflow
facility (P ¼ 0.008), and higher percent increase in
outflow facility (P ¼ 0.048). When comparing
implantation of the iStent Inject with implantation of the
Hydrus Microstent, Hydrus eyes showed higher outflow
facility (P < 0.001), higher increase in outflow facility
(P < 0.001), and higher percent increase in outflow
facility (P < 0.001).
Statistically, no difference was found in outflow facility
change between implantation of 2 iStent devices and 2
iStent Inject devices, probably because of the large standard
errors with the iStent Inject implants. The range of outcomes
for each device provides additional insight into the study
results. In terms of change in outflow facility, sham treat-
ment ranged from e53% to 29%. The Hydrus and 2 iStent
groups showed consistent improvement in outflow facility
compared with baseline. A single G1 iStent was less reliable
in improving outflow than 2 G1 iStents. The iStent Inject
showed the most variable outcome of all groups. Change in
outflow facility from baseline ranged from e65% to a
maximum of 127%. The highest value from the iStent Inject
group (127%) is better than the highest value seen in the
single G1 iStent group (74%) but lower than the highest
value observed with the 2 G1 iStents group (190%).117
Figure 4. Graph showing the results of study 2, implantation of 2 iStents
(G1) versus implantation of 2 iStent Injects (G2). Ten pairs of globes were
tested, with 1 randomly assigned globe receiving 2 G1s (n ¼ 8) and the
fellow eye receiving 2 G2s (n ¼ 10). The percent change in outflow facility
from baseline was not significantly different within groups, nor when
comparing groups. The bars indicate percent change from baseline outflow
facility (mean  standard error of the mean).
Ophthalmology Glaucoma Volume 3, Number 2, March/April 2020However, the lowest value from the iStent Inject group is
similar to that for the sham group (e65% vs. e53%). These
data suggest that the iStent Inject device is less predictable
than either single or dual G1 iStent implantation.
Previously published studies have investigated multiple
iStent and iStent Inject implants using an organ culture
perfusion model in which eyes were perfused with culture
media for days at a set flow rate of 2.5 ml/minute. The first
study reported an outflow facility increase of 0.10 ml/minute
per millimeter of mercury from a baseline of 0.12 ml/minute
per millimeter of mercury to 0.22 ml/minute per millimeter
of mercury with a single iStent (n ¼ 9). No outflow facility
data were reported on implantation of 2 iStents, although itFigure 5. Graph showing the results of study 3, implantation of 2 iStent
Injects (G2) versus implantation of 1 Hydrus Microstent. Eleven pairs of
globes were tested, with 1 randomly assigned globe receiving 2 G2s and the
fellow eye receiving 1 Hydrus Microstent. In the Hydrus Microstent globes,
the percent changes in outflow facility from baseline (P ¼ 0.001) and from
the 2 G2s (P ¼ 0.018) were significant. The bars indicate percent change
from baseline outflow facility (mean  standard error of the mean).
118was stated that no significant difference was seen.13 The
second study reported an outflow facility increase of 0.22
ml/minute per millimeter of mercury from a baseline of
0.160.05 ml/minute per millimeter of mercury to
0.380.23 ml/minute per millimeter of mercury with a
single iStent Inject (n ¼ 7). This study also reported an
outflow facility increase of 0.63 ml/minute per millimeter
of mercury from a baseline of 0.150.05 ml/minute per
millimeter of mercury to 0.780.66 ml/minute per
millimeter of mercury with 2 iStent Injects, although the
number was extremely small (n ¼ 2).14 The third study,
which used whole globes, reported only pressures, but an
outflow facility increase of 0.05 ml/minute per millimeter
of mercury from a baseline of 0.13 ml/minute per
millimeter of mercury to 0.18 ml/minute per millimeter of
mercury with a single iStent (n ¼ 3) can be calculated
using the Goldmann equation. This study also reported
results with implantation of 2 iStents, which showed an
increase of 0.10 ml/minute per millimeter of mercury from
a baseline of 0.13 ml/minute per millimeter of mercury to
0.23 ml/minute per millimeter of mercury (n ¼ 3).18
Procedural differences between those study methods and
methods reported in the current article make comparison
of the results difficult. In addition, comparing results with
different baseline values can be problematic. It has been
shown that the resulting outflow resistance ðR ¼ 1C Þ, and
therefore the change in resistance, is dependent on the
baseline outflow resistance. That is, higher baseline
outflow resistance values correlate with larger changes in
outflow resistance.11 Because the baseline outflow
resistance values in the previous studies were lower than
those in the current study, the percent changes of outflow
facility they showed could be exaggerated. Combine that
factor with small numbers of eyes tested in those studies,
and comparisons with the current study become unfeasible.
The MIGS devices in the current study increased C using
TM bypass and SC dilation to improve outflow directly into
SC. The resulting C was correlated positively to the size of
the inlet bypass and length of SC dilation. The iStent inlet
bypass was 1.5 times larger than iStent Inject. In addition, 1
iStent dilates up to 1 mm of SC compared with less than
0.25 mm of SC dilation seen with 1 iStent Inject device.16
Subsequently, the data showed that 2 iStents improved
outflow facility more than 2 iStent Injects with a
difference of 36.6%, although this was not significant
(n ¼ 8; P ¼ 0.271). When the TM inlet bypass of the
Hydrus Microstent was 2 times larger than that of the
iStent and 3 times larger than that of the iStent Inject, the
SC dilation with the Hydrus Microstent was 8 times more
than that of 1 iStent and approximately 32 times more
than that of 1 iStent Inject. Overall, in the current study,
the Hydrus Microstent increased C more than the smaller
MIGS devices, with the smallest MIGS device affecting C
the least.
Placing a 1-mm slit in the TM without implanting a stent,
as was carried out in the sham procedure, has minimal effect
on C. Placing a small bypass device such as the iStent Inject
does increase C more than sham but not as much as the
larger bypass MIGS devices, the iStent and Hydrus Micro-
stent. The larger bypass lumen of the iStent increased C
Figure 6. Graph showing percent change from baseline of all study results. Data collected from all experiments on each implant were averaged, and the
results were compared. The bars show percent changes from baseline outflow facility (mean  standard error of the mean) in globes treated with sham
procedure (sham), implantation of 2 iStent Injects (G2), implantation of 1 iStent (G1), implantation of 2 G1s, and implantation of 1 Hydrus Microstent.
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or 2 stents were placed. These results suggest that a large
patent bypass is critical to C increase. This could also be
because of the 1 mm of SC dilation from the iStent, which
may provide more access to collector channels than the
iStent Inject. The Hydrus Microstent has the largest inlet
bypass and dilates SC to a greater extent, which could help
to explain the significant increase in C. It is postulated that
the greater length of SC dilated provides greater access to
collector channels and greater outflow potential. A mathe-
matical model19 shows that the TM bypass provides the
most effect when placed relatively close to a collector
channel. In cases where the TM bypass is farther from a
collector channel, SC dilation helps to provide lower
resistance for flow to that collector channel. Additionally,
the larger the region of SC dilation, the less dependent the
placement location of the TM bypass.17
Evidence supports that placement of these MIGS devices
into SC is critical to their efficacy. First, the bypass must be
patent. If the bypass does not cross the TM fully or is buried
so deep that the opening is covered, the outflow through the
stent can be compromised. Even with direct visualization of
the TM and SC, as in the current study, confirmation of the
exact placement at times can be difficult. In live patients,
surgeons not only have to view the angle through a gonio-
lens and fluid-filled eye, they also have to clear refluxed
blood that can obscure the stent placement further. Although
it is a critical consideration for all outflow MIGS devices,
because of their extremely small size, iStent Inject implants
pose a significant challenge in this regard. Conversely, theHydrus Microstent is large enough that placement in SC is
readily confirmed. Finally, the position of the stents relative
to collector channels, as mentioned above, is also a practical
challenge during the surgical placement of these devices.
Advanced techniques used to target placement, not per-
formed in this study, such as identifying pigmented areas of
TM, inducing blood reflux into SC, or intraoperative
assessment of the aqueous outflow network, can impact the
results of these procedures positively.20 Such intraoperative
clues are more evident in a live patient than a cadaver eye.
The Hydrus Microstent’s size may offer an advantage in this
regard as well, because its relatively long length provides
access to more collector channels, obviating the need for
such intraoperative clues.
Comparison of implantation of the Hydrus Microstent
and 2 iStents in human clinical trials was published
recently.21 The study was a prospective, multicenter,
randomized trial comparing implantation of the Hydrus
Microstent and 2 iStents in standalone surgery. Eligible
patients had mild to moderate open-angle glaucoma that
was treated with 2 to 4 glaucoma medications. The mean
numbers of medications before washout were 2.5 in the
Hydrus Microstent group and 2.7 in the 2 iStents group.
The baseline washed-out diurnal IOP was 27.54.4 mmHg
in eyes randomized to the Hydrus Microstent (n ¼ 75) and
27.34.2 mmHg in eyes randomized to 2 iStents (n ¼ 77).
Medications were reintroduced throughout follow-up as
needed if IOP exceeded 19 mmHg. At 12 months, IOP was
17.3 and 18.1 mmHg in the Hydrus Microstent and 2
iStents groups (P ¼ not significant). The number of119
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Microstent group and 1.01.2 in the 2 iStents group. The
between-group difference of e0.6 medications was signif-
icant (P ¼ 0.004). Although comparing ex vivo perfusion
testing and clinical trial results is difficult, the conclusions
of the recent clinical trial are consistent with the conclu-
sions of the current study. Larger increases in outflow fa-
cility translate to lower medication use in patients with the
Hydrus Microstent compared with patients receiving
2 iStents.
Despite the numerous differences between the design of
clinical trials and cadaver eye experiments, findings in the
nonglaucomatous cadaver eyes of the current study as well
as clinical trials of SC MIGS devices support the same idea,
that is, that the longer the MIGS device and the more SC it
dilates, the greater the outflow facility, the lower the IOP,
and reduced the need for topical ocular hypotensive medi-
cations. Larger SC MIGS devices in the glaucoma arma-
mentarium can provide a favorable choice for the glaucoma
patient and clinician.
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